Redeye notes that the Q2 report from Vicore did not include any surprises. We provide a brief comment on the financials and highlight the most important events during the period. We argue that the upcoming trial readouts this autumn (Covid-19 and SSc) will attract interest from investors, and we expect to see some speculation prior to these readouts.